• Main Menu
  • ABOUT
    • About Amgen

      Explore the legacy and impact of Amgen, a pioneering biotechnology firm revolutionizing medicine through innovative biological drugs and cutting-edge research.

    • Amgen History

      Explore Amgen's extensive history of over 35 years, marked by groundbreaking therapeutic innovation. Learn about our journey shaping the future of healthcare.

    • Mission & Values

      Amgen's mission is to harness the potential of science and biotechnology to develop life-saving therapies, guided by values like ethics, teamwork, and quality.

    • Contact Us

      Connect with Amgen for inquiries and assistance. Access our contact form and essential information on media, investors, careers, and more.

    • Our Medicines

      Discover Amgen's array of innovative prescription drugs aimed at treating serious illnesses. Explore our impactful therapies dedicated to improving lives.

    • Leadership

      Connect with Amgen for inquiries and assistance. Access our contact form and essential information on media, investors, careers, and more.

    • Partnerships
    • Collaborative Working and Joint Initiatives
    • Next Generation Population Health
    • QuicDNA
  • SCIENCE
    • Overview

      Discover how Amgen's innovations in biotechnology are shaping the future of medicine. Explore our pioneering role in advancing science to transform lives.

    • Clinical Trials

      Understanding clinical trials, including risks, benefits, placebos, participation, and regulations. Learn how to get involved and what to expect.

    • Biotechnology
    • The Science of Biotechnology
    • Discovering and Developing Medicines
    • Biosimilars

      Explore Amgen's expertise in biosimilars backed by over 40 years of biotechnology experience. Learn about biosimilar basics, manufacturing, and more.

    • Biomanufacturing
    • How Are Biotechnology Medicines Made?
  • THERAPEUTIC AREAS
    • Overview

      Explore Amgen's commitment to advancing healthcare across key areas: oncology, cardiovascular disease, osteoporosis, and more.

    • Pharmacovigilance

      Delve into Amgen's pharmacovigilance commitment, ensuring safety and efficacy of our medicines. Learn about our rigorous monitoring and reporting practices.

  • Responsibility
    • Overview

      Amgen strives to make a difference through the Foundation, environmental initiatives, ethics, and more. Discover our impactful programs and achievements.

    • Environment, Social and Governance

      Explore Amgen's ESG commitment for a better world: Healthy People, Society, Planet, and a Healthy Amgen. Serving patients and global well-being.

    • Diversity, Inclusion and Belonging

      Discover Amgen's commitment to diversity, inclusion and belonging, fostering an innovative, welcoming work environment for all.

    • Ethics and Compliance

      Amgen upholds ethical conduct and transparency in all business operations. Explore our Code of Conduct, Compliance Policy, and reporting mechanisms.

    • The Amgen Foundation

      The Amgen Foundation is an integral component of Amgen’s commitment to dramatically improve people’s lives.

    • Transparency

      Access Amgen's transparency reports. Learn about our commitment to openness and accountability.

    • Collaborative Working
    • Patient Advocacy Groups
    • Members of the Public
  • Newsroom
  • Working at Amgen
  • amgen-worldwide-web
  1. Home
    >
  2. Media
    >
  3. >

By selecting the Yes option, Leave Amgen.co.uk option, you understand that you are leaving the corporate page of Amgen UK and that you will be redirected to another Internet site belonging to third parties, for whose content or opinions Amgen Europe is not responsible and makes no representations regarding such content or its accuracy. By selecting this option and accessing linked third party sites, you understand that you do so at your own risk.

The website to which you will be redirected may be designed exclusively for residents of a particular country or countries, as advertised on that website. As a consequence, the website to which you will be directed may contain information on pharmaceutical products or indications that are not approved in Europe. If You reside in a country other than the one to which such website is directed, please contact your local Amgen affiliate for the correct information on products in your country of residence.

yes, leave amgen.co.uk CANCEL
2025

May 2025

  • 12.05.2025 | NEWS

    Amgen’s TEPEZZA®▼ (teprotumumab) granted marketing authorisation as the first targeted treatment specifically for adults with moderate-to-severe Thyroid Eye Disease (TED) in the United Kingdom

April 2025

  • 11.04.2025 | NEWS

    Amgen’s Russell Abberley, Vice President & General Manager UK & Ireland, formally elected as President of The Association of the British Pharmaceutical Industry (ABPI)

January 2025

  • 01.01.2025 | NEWS

    Amgen’s IMDYLLTRA®▼ (tarlatamab) granted a conditional marketing authorisation for third-line treatment of extensive-stage small cell lung cancer in the United Kingdom

GBR-632-0525-80005 | May 2025

Contact Us Terms of Use Privacy Statement Cookie Preferences Cookie Statement Sitemap

    © 2008-2025 Amgen Limited. All Rights Reserved.